30 closest matches · ranked by relevance
Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
Primary: P2Y12 Reaction Units (PRU) - Part A — 301.6; 268.0; 295.4; 287.7 P2Y12 reaction units
Sickle Cell Disease
Primary: Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Prasugrel Active Metabolite (Pras-AM) — 8.68; 14.5; 20.8; 31.3 nanograms*hour per milliliter (ng*hr/mL)
Chronic Kidney Disease
Primary: Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid — 21.0; 18.0; 0; 0 ohms
Anemia, Sickle Cell
Primary: Area Under the Plasma Concentration-Time Curve (AUC) From Time of Dosing Through the Sampling Time of the Last Quantifiable Concentration [AUC(0-tlast)] for Prasugrel's…
Sickle Cell Anemia
Primary: Percentage of Participants With Hemorrhagic Events Requiring Medical Intervention During the Treatment Duration — 0; 0 percentage of participants
Sickle Cell Disease
Primary: Number Participants With Most Common Reported Drug Related Adverse Events — 6; 3; 3 Participants
Myocardial Infarction
Primary: LogEC50 Platelet Aggregation — 2.65; 2.62 nM
Sickle Cell Disease
Primary: Number of Serious Adverse Events — 6; 9; 0; 0 events
Diabetes Mellitus With Hypoglycemia · Diabetes Mellitus, Type 2 · Hypoglycemia
Primary: Changes in Platelet Activation Marker Adenosin Diphosphate (%) — 63; 64.4; 64.4; 61.1 percentage of ADP
Cardiovascular Disease · Peripheral Artery Disease · Critical Limb Ischemia
Primary: Number of Patients in Which Platelet Activity Measurements Were Associated With Short-term Cardiovascular Events — 31; 16 participants
HIV · Cardiovascular Diseases · Inflammation
Primary: Percentage Platelet Aggregation in PRP After Stimulation With Arachidonic Acid 1600 μM for 5 Min — 72.35; 79.11; 72.79; 26.77 %aggregation
Sickle Cell Disease
Primary: Change in Proportion of Days With Pain Due to Sickle Cell Disease as Measured by an eDiary — -0.1802; -0.1352; -0.1001 Proportion of days with pain
Thrombocytopenia
Primary: Change in Post-transfusion Platelet Counts — 99; 97.5 Platelets (*10^3/mm^3) — p=0.8
Sickle Cell Disease
Primary: SS RBC Adhesion (Epi -1d/cm2- vs. Sham) by Treatment — 0; -0.3; 7.4; 2.7 Percentage of total RBC
Systolic Heart Failure
Primary: The Change in Platelet Aggregation Measured by the Accumetrics (VerifyNow P2Y12) Assay Between Baseline and Each Antiplatelet Medication — 66.4; 156.2 PRU (P2Y12…
Idiopathic Thrombocytopenic Purpura
Primary: Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1 — 1; 25 Participants…
Stroke · Myocardial Infarctions
Primary: PFA1 — 202.0; 271.1; 234.7 seconds — p=0.0742
Sickle Cell Anemia
Primary: Change From Baseline of 4- Week Average Daily Pain Measured by Visual Analog Score (VAS) Over the Period of Week 8 to 12 — -0.45; -0.37 Score on a scale — p=0.55
Heart Defects, Congenital
Primary: Number of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure < 120 Days Considered of Thrombotic Nature)…
Sickle Cell Disease
Primary: To Determine the Pharmacokinetics of Methadone in Children and Adults With Sickle Cell Disease Experiencing a VOE. — 523; 0; 637; 0 (hr*ng/ml)
Sickle Cell Disease
Primary: Level of Satisfaction on SCD Current Treatment and Management — 4.12 score on a scale
Bleeding
Primary: Calculated Blood Loss — 1996 milliters
Sickle Cell Disease
Primary: Mean Change in the Plasma Soluble P-selectin Level — 0.74; 0.10 ng/ml — p=0.64
Sickle Cell Disease (SCD)
Primary: Pharmacokinetics (PK): AUCd15 of Crizanlizumab After First Dose - Part A — 10500; 8180; 20600; 14400 hr*ug/mL
Sickle Cell Disease · Sickle Cell Trait · Beta-Thalassemia
Primary: Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value — 96.6; 100; 0; 91.3 percentage
Sickle Cell Anemia · Sickle Cell-Beta0-Thalassemia
Primary: Change From Baseline to 4 Weeks in Soluble Vascular Cell Adhesion Molecule-1 (VCAM-1) — 40.9; 10.7 pg/mL — p=0.6281
Sickle Cell Disease
Primary: Full Scale IQ (FSIQ) (WASI) — 86.43; 88.0 scores on a scale
Blood Platelet Disorders
Primary: Response to Drug Based on Platelet Count at the End of Therapy — 91.6 percentage of participants
Cardiac Disease · Cardiac Surgery · Cardiopulmonary Bypass
Primary: Amount of Blood Products Transfused — 58; 103 milliliter per kilogram (mL/kg)
Phase 1 Sickle Cell
Primary: Number of Participants With Potentially Clinically Important (PCI) Change From Baseline in Vital Signs — 0; 0; 0; 2 participants